Clinical Research Trials

Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.

Y-HEP Health Center | Jonathan Lax Health Center


The following clinical trials are ongoing at the Lax Center and currently enrolling patients:

A Phase 3b multi-center, open label, single arm, 48-week study, evaluating efficacy and safety of a rapid Test and Treat intervention in newly diagnosed HIV-1 infected adults using fixed dose dolutegravir plus lamivudine as a first line regimen [STAT]

Trial Number: 212355Description: An open-label pilot examining the safety and efficacy of a single tablet, two-drug regimen to treat HIV delivered in a rapid, test-and-treat model of care.

BEAT-HIV Delaney Collaboroatory

Are you interested in HIV cure-directed research? The Philadelphia based BEAT-HIV Delaney Collaboroatory is a group of more than 60 of the top HIV scientists from around the world working to advance the HIV cure research agenda. To get involved in an HIV cure-directed research trial, please call Linden Lalley-Chareczko, Research Program Director, at 215-525-8695.


The following clinical trials are ongoing at the Lax Center but are NOT enrolling new patients:

Open-label study to evaluate switching from a regimen of two NRTIs plus a third agent to a fixed dose combination of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected, African American participants

Trial number: GS-US-380-4580

Description: A phase 3b, open-label study to evaluate switching from a regimen of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus a third agent to a fixed dose combination (FDC) of bectegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed, HIV-1 infected, African American participants.

Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis (PrEP)

Trial Number: GS-US-412-2055

Description: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women who have Sex with Men and are at Risk of HIV-1 Infection

Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Triumeq in HIV+, Treatment-Naïve Adults

Trial Number: GS-US-380-1489

Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 infected, antiretroviral treatment-naïve adults

Randomized, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed [TANGO]

Trial Number: 204862

Description: A phase 3, randomized study aiming to determine the efficacy, safety and tolerability of two approved medicines, dolutegravir (DTG) plus lamivudine (3TC) taken together, compared with subjects taking their current tenofovir alafenamide (TAF)-based regimen (TBR) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed.

Switch Study to Evaluate D/C/F/TAF, Once-Daily versus Staying on a Boosted Protease Inhibitor Regimen

Trial Number: TMC114IFD3013
Description: A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily, single-tablet regimen versus continuing the current regimen consisting of a boodted protease inhibitor (bPI) combined with emtricitabine/tenofovir disproxil fumerate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus, type-1 (HIV-1) infected subjects

The Immunopathogenisis of HIV

Description: Sponsored by The Wistar Institute


The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:

There are currently no trials enrolling at YHEP Health Center. Please check back soon!

For more information on any of the clinical trials listed, please contact the Research Department at 215-525-8695.

Program Information

  • Phone: 215-525-8695

Spotlight On

Karam Mounzer, MD

Dr. Mounzer identified two major gaps in the care of patients with HIV/hepatitis C (HCV) co-infection, and the complexity of multidrug-resistant HIV treatment. He is involved with many clinical trials focusing on drug development and better understanding of HIV immunopathogenesis with the Wistar Institute. He is involved in teaching and mentoring.

Learn More about Spotlight On
Dr. Karam Mounzer

Dr. Mario Cruz

Dr. Mario CruzDr. Cruz is a board certified pediatrician who serves as the Medical Director for our Pediatrics and Adolescent Health Center. He has presented and/or published in the fields of community violence and domestic violence prevention, quality improvement, behavioral health, curriculum development and mentorship. In 2019 he received the Greater Philadelphia Social Innovation Award for Innovations in Healthcare.


Translate »